Projections of Type 1 and Type 2 Diabetes Burden in the U.S. Population Aged <20 Years Through 2060: The SEARCH for Diabetes in Youth Study

OBJECTIVE
To project the prevalence and number of youths with diabetes and trends in racial and ethnic disparities in the U.S. through 2060.
RESEARCH DESIGN AND METHODS
Based on a mathematical model and data from the SEARCH for Diabetes in Youth study for calendar years 2002–2017, we projected the future prevalence of type 1 and type 2 diabetes among youth aged <20 years while considering different scenarios of future trends in incidence.
RESULTS
The number of youths with diabetes will increase from 213,000 (95% CI 209,000; 218,000) (type 1 diabetes 185,000, type 2 diabetes 28,000) in 2017 to 239,000 (95% CI 209,000; 282,000) (type 1 diabetes 191,000, type 2 diabetes 48,000) in 2060 if the incidence remains constant as observed in 2017. Corresponding relative increases were 3% (95% CI −9%; 21%) for type 1 diabetes and 69% (95% CI 43%; 109%) for type 2 diabetes. Assuming that increasing trends in incidence observed between 2002 and 2017 continue, the projected number of youths with diabetes will be 526,000 (95% CI 335,000; 893,000) (type 1 diabetes 306,000, type 2 diabetes 220,000). Corresponding relative increases would be 65% (95% CI 12%; 158%) for type 1 diabetes and 673% (95% CI 362%; 1,341%) for type 2 diabetes. In both scenarios, substantial widening of racial and ethnic disparities in type 2 diabetes prevalence are expected, with the highest prevalence among non-Hispanic Black youth.
CONCLUSIONS
The number of youths with diabetes in the U.S. is likely to substantially increase in future decades, which emphasizes the need for prevention to attenuate this trend.

Bekijk het originele bericht

Wellicht vindt u dit ook interessant

Meld u aan voor de maandelijkse nieuwsbrief

Patiëntvoorbeelden m.b.t. vergoeding

Voeg je koptekst hier toe

Vergoeding diabetesmiddelen

Apothekersinstructies:

Er zijn 2 soorten terugbetalingsregelingen:
* TBR: patiënt declareert online of per post of de apotheker declareert namens de patiënt online
** HEVO-Consult: patiënt betaalt kosten eerst zelf en stuurt declaratie naar HEVO-Consult